Skip to main content
Top
Published in: Pediatric Radiology 6/2015

01-06-2015 | Original Article

Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children

Authors: Nichanan Ruangwattanapaisarn, Albert Hsiao, Shreyas S. Vasanawala

Published in: Pediatric Radiology | Issue 6/2015

Login to get access

Abstract

Background

Ferumoxytol is an ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle agent used to treat iron deficiency anemia in adults with chronic kidney disease.

Objective

We aim to determine the feasibility of using ferumoxytol for clinical pediatric cardiac and vascular imaging.

Material and methods

We retrospectively identified 23 consecutive children who underwent MRI with ferumoxytol (11 males; mean age: 7.4 years, range: 3 days–18 years), yielding 12 abdominal MR angiography and 15 cardiac MRI studies. Medical records were reviewed for the clinical indication, ferumoxytol dose, injection rate, sedation and any complication. A two-reader consensus scored the images on a five-point scale for overall image quality and delineation of various anatomical structures. Signal-to-background ratios for abdominal aorta and inferior vena cava for abdominal cases and blood pool-myocardium contrast ratios for cardiac cases were calculated. The confidence intervals for obtaining a score of three or above for each image parameter were calculated by using adjusted Wald method.

Results

For abdominal MR angiography, average scores for overall image quality, as well as delineation of the hepatic artery, superior mesenteric artery, renal artery and veins were 4.5, 4.3, 4.3, 3.7 and 4.7, respectively. For cardiac exams, the average scores for overall image quality, systemic arteries, pulmonary arteries, pulmonary veins, valves and ventricles were 4.4, 4.6, 4.1, 4.8, 4.1 and 4.7, respectively. For all parameters, the lower bound for the proportion of cases to have a score of 3 or above was 65%. Signal-to-background ratios for aorta and abdominal veins averaged 86 +/− 74 and 86 +/− 77 for full-dose images, and 23 and 18 for half-dose images, respectively. Mean blood pool to myocardium contrast ratio was 3:3.

Conclusion

Ferumoxytol can provide excellent image quality for pediatric body MR angiography/MR venography at a dose of 1.5 or 3 mg Fe/kg. Further investigation should be directed toward understanding the lowest dose that can be administered.
Literature
1.
go back to reference Prince MR, Zhang HL, Chabra SG et al (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231–240PubMed Prince MR, Zhang HL, Chabra SG et al (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231–240PubMed
2.
go back to reference Li W, Tutton S, Vu AT et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21:46–52CrossRefPubMed Li W, Tutton S, Vu AT et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21:46–52CrossRefPubMed
3.
go back to reference Bremerich J, Bilecen D, Reimer P (2007) MR angiography with blood pool contrast agents. Eur Radiol 17:3017–3024CrossRefPubMed Bremerich J, Bilecen D, Reimer P (2007) MR angiography with blood pool contrast agents. Eur Radiol 17:3017–3024CrossRefPubMed
4.
go back to reference Bashir MR, Mody R, Neville A et al (2014) Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging 40:113–118CrossRefPubMed Bashir MR, Mody R, Neville A et al (2014) Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging 40:113–118CrossRefPubMed
5.
go back to reference Sigovan M, Gasper W, Alley HF et al (2012) USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 265:584–590PubMedCentralCrossRefPubMed Sigovan M, Gasper W, Alley HF et al (2012) USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 265:584–590PubMedCentralCrossRefPubMed
6.
go back to reference Ersoy H, Jacobs P, Kent CK et al (2004) Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol 182:1181–1186CrossRefPubMed Ersoy H, Jacobs P, Kent CK et al (2004) Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol 182:1181–1186CrossRefPubMed
7.
go back to reference Gahramanov S, Muldoon LL, Varallyay CG et al (2013) Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 266:842–852PubMedCentralCrossRefPubMed Gahramanov S, Muldoon LL, Varallyay CG et al (2013) Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 266:842–852PubMedCentralCrossRefPubMed
8.
go back to reference Hamilton BE, Nesbit GM, Dosa E et al (2011) Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 197:981–988PubMedCentralCrossRefPubMed Hamilton BE, Nesbit GM, Dosa E et al (2011) Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 197:981–988PubMedCentralCrossRefPubMed
9.
go back to reference Li W, Salanitri J, Tutton S et al (2007) Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism–preliminary experience. Radiology 242:873–881CrossRefPubMed Li W, Salanitri J, Tutton S et al (2007) Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism–preliminary experience. Radiology 242:873–881CrossRefPubMed
10.
go back to reference McCullough BJ, Kolokythas O, Maki JH et al (2013) Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 37:1476–1479CrossRefPubMed McCullough BJ, Kolokythas O, Maki JH et al (2013) Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 37:1476–1479CrossRefPubMed
11.
go back to reference Stabi KL, Bendz LM (2011) Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Ann Pharmacother 45:1571–1575CrossRefPubMed Stabi KL, Bendz LM (2011) Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Ann Pharmacother 45:1571–1575CrossRefPubMed
12.
go back to reference Thompson EM, Guillaume DJ, Dosa E et al (2012) Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurol 109:105–114 Thompson EM, Guillaume DJ, Dosa E et al (2012) Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurol 109:105–114
13.
go back to reference Schiller B, Bhat P, Sharma A (2013) Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 36:70–83CrossRefPubMed Schiller B, Bhat P, Sharma A (2013) Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 36:70–83CrossRefPubMed
14.
go back to reference Schieda N (2013) Parenteral ferumoxtol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning. Insights Imaging 4:509–512PubMedCentralCrossRefPubMed Schieda N (2013) Parenteral ferumoxtol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning. Insights Imaging 4:509–512PubMedCentralCrossRefPubMed
15.
go back to reference Institute of Medicine, Food and Nutrition Board (2011) Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc : a report of the panel on micronutrients. National Academy Press, Washington, DC Institute of Medicine, Food and Nutrition Board (2011) Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc : a report of the panel on micronutrients. National Academy Press, Washington, DC
Metadata
Title
Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children
Authors
Nichanan Ruangwattanapaisarn
Albert Hsiao
Shreyas S. Vasanawala
Publication date
01-06-2015
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Radiology / Issue 6/2015
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-014-3226-3

Other articles of this Issue 6/2015

Pediatric Radiology 6/2015 Go to the issue